SWMG
IBRX icon

Strategic Wealth Management Group’s ImmunityBio IBRX Stock Holding History

Strategic Wealth Management Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,926
Closed -$378K – 128
2021
Q1 		$378K Buy
+15,926
New +$413K 0.14% 86

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Strategic Wealth Management Group's IBRX Position: Q2 2021 in Review

Strategic Wealth Management Group sold out of ImmunityBio (IBRX) in Q2 2021, closing a stake of 15,926 shares — an estimated $378K sold.

Strategic Wealth Management Group first reported a position in IBRX in Q1 2021 and held it in 1 quarter. The position peaked at $378K in Q1 2021. 125 funds tracked by Wall St. Rank hold IBRX as of Q2 2021.

  • Strategic Wealth Management Group reported no remaining ImmunityBio position as of Q2 2021 after selling out during the quarter.
  • Strategic Wealth Management Group sold 15,926 ImmunityBio shares in Q2 2021, an estimated $378K.
  • Strategic Wealth Management Group first reported a position in ImmunityBio in Q1 2021 and held it in 1 quarter.
  • Strategic Wealth Management Group's ImmunityBio position peaked at $378K in Q1 2021.
  • 125 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2021.

Based on Strategic Wealth Management Group's 13F filing for Q2 2021, filed 13 Aug 2021.